Gilead Sciences is already underway with a phase III study of idelalisib in patients with advanced CLL. The drug is also being studied in indolent non-Hodgkins lymphoma.
Idelalisib works by blocking a protein known as PI3K-delta which is critical for tumor cell growth. PI3K inhibition is a hot molecular target in cancer drug research, being pursued by multiple companies including Infinity Pharmaceuticals (INFI), Roche (RHHBY), Novartis (NVS), TG Therapeutics (TGTX) and Oncothyreon (ONTY), according to BioMedTracker.
Investors have been even more excited about the strong efficacy results posted by Pharmacyclics' ibrutinib, which blocks a related cell-growth signal known as Bruton's Tyrorisine Kinase (BTK.)
-- Reported by Adam Feuerstein in Boston.Follow @AdamFeuerstein
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV